Precision-Cut Bronchial Tissue Model for Viral Tropism Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the risk of respiratory viral infections, such as influenza and coronaviruses, face challenges in accurately evaluating virus tropism and replication competence due to limitations in traditional cell culture models and animal models, particularly in reflecting human lung tissue architecture and receptor diversity, leading to difficulties in predicting pandemic threats.
Innovation Solution
A method involving precision-cut human bronchial tissues is developed to create an ex vivo model for analyzing viral infectivity, tropism, and pathogenesis, using reference virus strains like the 2009 H1N1 pandemic virus and HPAI H5N1 virus, with a semi-quantitative approach to assess pandemic risk by preparing and infecting bronchial tissues to mimic human respiratory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cell culture models are used to assess viral infections, then the research process is simple and fast, but the models poorly reflect the cellular composition, matrix complexity, and three-dimensional architecture of the human lung
Solution Approach 1:
The patent creates ex vivo human lung tissue models that replicate the three-dimensional architecture, cellular composition, and matrix complexity of native human lung tissue. These tissue models serve as realistic copies that maintain physiological relevance while enabling controlled experimental conditions, thus resolving the contradiction between biological fidelity and experimental simplicity.
Solution Approach 2:
The patent performs preliminary dissection and preparation of human lung tissues to expose the epithelium before viral infection experiments. By pre-processing the tissues to achieve optimal architectural preservation and epithelial exposure, the method enables subsequent experiments to proceed with high reliability without requiring complex real-time manipulations during infection studies.
2Reliability
If animal models are used to study respiratory viruses, then the models provide valuable insights into disease mechanisms, but species differences limit their applicability to human zoonotic lung diseases
Solution Approach 1:
The patent uses human lung tissue models that directly replicate human respiratory epithelium and cellular architecture, eliminating species differences that limit animal model applicability. These human-derived tissue models provide biologically relevant data for human zoonotic diseases while maintaining the versatility to study various virus types and transmission modes.
3Measurement precision
If ex vivo human lung tissue models are used to study viral tropism and replication, then the models provide accurate human-relevant data, but the tissue preparation and dissection process is complex and requires exposing the epithelium
Solution Approach 1:
The patent performs preliminary dissection steps to expose the epithelium and prepare the tissue architecture before viral infection. By completing these complex preparation steps in advance, the method establishes optimized tissue models that enable precise measurement of viral tropism and replication without requiring complex manipulations during the actual infection experiments.
Solution Approach 2:
The patent divides the lung tissue into smaller, manageable segments that can be individually processed and infected. This segmentation approach simplifies the dissection process while preserving the three-dimensional architecture and cellular composition necessary for accurate viral tropism and replication assessment.
4Adaptability or versatility
If risk assessment algorithms like IRAT and TIPRA are used to evaluate pandemic threats, then the assessments cover multiple virus properties and ecology factors, but the algorithms lack direct measurement of viral replication competence in human airways
Solution Approach 1:
The patent introduces ex vivo human lung tissue models as an intermediary system that bridges the gap between indirect algorithmic risk assessments and direct measurement of viral replication competence. These tissue models serve as a physiological mediator that enables direct experimentation while maintaining the comprehensive evaluation framework of existing risk assessment algorithms.
Data Source
AI summary
The present invention relates to a method for assessing respiratory viral infections, the method includes preparing one or more precision-cut human bronchial tissues; exposing a cilia-rich epithelium within the precision-cut human bronchial tissues to establish an ex vivo model of human bronchus for viral infections; assessing infectivity, tropism, and pathogenesis of one or more respiratory viruses in the ex vivo model; and providing a semi-quantitative and normalized approach to supplement data from the ex vivo model of human bronchus for pandemic risk assessment of the one or more respiratory viruses. The present invention involves micro-dissection of bronchial tissues to expose the cilia-rich epithelium for ex vivo virus infection, along with a semi-quantitative approach for analyzing virus tropism and replication competence.